Cargando…

Value of the HFA‐PEFF and H(2)FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis

AIMS: The HFA‐PEFF and H(2)FPEF scores have been developed to diagnose heart failure with preserved ejection fraction (HFpEF), and hold prognostic value. Their value in patients with HFpEF caused by cardiac amyloidosis (CA) has never been investigated. METHODS AND RESULTS: We evaluated the diagnosti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomasoni, Daniela, Aimo, Alberto, Merlo, Marco, Nardi, Matilde, Adamo, Marianna, Bellicini, Maria Giulia, Cani, Dario, Franzini, Maria, Khalil, Anas, Pancaldi, Edoardo, Panichella, Giorgia, Porcari, Aldostefano, Rossi, Maddalena, Vergaro, Giuseppe, Lombardi, Carlo Mario, Sinagra, Gianfranco, Rapezzi, Claudio, Emdin, Michele, Metra, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	Cardiac Amyloidosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087855/ https://www.ncbi.nlm.nih.gov/pubmed/35855616 http://dx.doi.org/10.1002/ejhf.2616

Ejemplares similares

Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies
por: Aimo, Alberto, et al.
Publicado: (2022)

The HFA‐PEFF and H(2)FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction
por: Sanders‐van Wijk, Sandra, et al.
Publicado: (2020)

The H(2)FPEF and HFA-PEFF algorithms for predicting exercise intolerance and abnormal hemodynamics in heart failure with preserved ejection fraction
por: Amanai, Shiro, et al.
Publicado: (2022)

Prognostic Impact of the HFA-PEFF Score in Patients with Acute Myocardial Infarction and an Intermediate to High HFA-PEFF Score
por: Lee, Kwan Yong, et al.
Publicado: (2022)

Applying the ESC 2016, H(2)FPEF, and HFA‐PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population
por: Nikorowitsch, Julius, et al.
Publicado: (2021)

Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
por: Patel, Rishi K., et al.
Publicado: (2022)

Comparing the Diagnostic Performance of HFA-PEFF and H2FPEF Scoring Systems in Heart Failure with Preserved Ejection Fraction Patients: Insights from the APOLLON Registry
por: Mert, Gurbet Özge, et al.
Publicado: (2023)

Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
por: Chacko, Liza, et al.
Publicado: (2022)

Disagreement of ESC guidelines from 2016 and 2021 and HFA-PEFF and H2 FPEF scores in diagnosis of heart failure with preserved ejection fraction in atrial fibrillation patients
por: Gawalko, M, et al.
Publicado: (2023)

Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value
por: Cipriani, Alberto, et al.
Publicado: (2022)

Restrictive cardiomyopathy: definition and diagnosis
por: Rapezzi, Claudio, et al.
Publicado: (2022)

Evaluation of the HFA‐PEFF Score: results from the prospective DIAST‐CHF cohort
por: Hashemi, Djawid, et al.
Publicado: (2022)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

Predictive Value of HFA-PEFF Score in Patients With Heart Failure With Preserved Ejection Fraction
por: Sun, Yuxi, et al.
Publicado: (2021)

Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction
por: Sotomi, Yohei, et al.
Publicado: (2021)

Prognostic Value of HFA-PEFF Score in Patients Undergoing Transcatheter Aortic Valve Implantation
por: Alotaibi, Sultan, et al.
Publicado: (2022)

Haemodynamic validation of the three‐step HFA‐PEFF algorithm to diagnose heart failure with preserved ejection fraction
por: Lanzarone, Ettore, et al.
Publicado: (2023)

Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020)

The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles
por: Henkens, Michiel T.H.M., et al.
Publicado: (2022)

HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction
por: Egashira, Koichi, et al.
Publicado: (2022)

Diagnosing HFpEF and Predicting ESLD Liver Transplant Outcome Using HFA-PEFF Score
por: Lyu, Xiuhong
Publicado: (2023)

HFA‐PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation
por: Seoudy, Hatim, et al.
Publicado: (2022)

Value of the HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the inflammatory myopathy population
por: Shi, Yunjing, et al.
Publicado: (2023)

Transthyretin Cardiac Amyloidosis: A Noninvasive Multimodality Approach to Diagnosis Using Transthoracic Echocardiography, 99m-Tc-Labeled Phosphate Bone Scanning, and Cardiac Magnetic Resonance Imaging
por: Shukla, Akhil, et al.
Publicado: (2017)

Regression of the Anatomic Cardiac Features of Amyloid Light Chain Cardiac Amyloidosis Accompanied by Normalization of Global Longitudinal Strain
por: Fitzgerald, Benjamin T., et al.
Publicado: (2017)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
por: Klaassen, Sebastiaan HC, et al.
Publicado: (2020)

An Autopsy Case of Cardiac Amyloidosis with Heterogeneous Deposition of Amyloid Protein: A Possible Mechanism for Relative Apical Sparing of Longitudinal Strain
por: Sawada, Naoko, et al.
Publicado: (2019)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Relative importance of left atrial reservoir strain compared with components of the HFA-PEFF score: a cross-sectional study
por: Kim, Minkwan, et al.
Publicado: (2023)

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
por: Tomasoni, Daniela, et al.
Publicado: (2023)

Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings
por: Hadzibegovic, Sara, et al.
Publicado: (2021)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
por: Sanguinetti, Chiara, et al.
Publicado: (2022)

Exploring the possible link between myocarditis and mRNA COVID-19 vaccines
por: Sinagra, Gianfranco, et al.
Publicado: (2021)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Prognostic impact of the updated 2018 HFA‐ESC definition of advanced heart failure: results from the HELP‐HF registry
por: Pagnesi, Matteo, et al.
Publicado: (2022)

COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae
por: Italia, Leonardo, et al.
Publicado: (2021)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022)

Editorial: Proceedings and predictions in cardiac amyloidosis: unsolved mysteries and challenges for the future
por: Porcari, Aldostefano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cc2thprfuu37s0g51du9j835q4